Accordingly, antibodies that block the interaction of CTLA-4 or PD-1 with their ligands are able to reinvigorate exhausted T cells and have shown long-term favorable responses in a percentage of cancer patients, including complete tumor regression and remission in patients with far-progressed cancers that were refractory to standard treatments [18,19,20]. Here, CTLA4 is linked to cancer.